WET AGE-RELATED MACULAR DEGENERATION
Clinical trials for WET AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new WET AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for WET AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
One-Shot gene therapy aims to free patients from frequent eye injections
Disease control Recruiting nowThis study is testing a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (wet AMD), a leading cause of vision loss. The goal is to see if this single treatment can help the eye make its own medicine, reducing or eliminating the need for li…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Could a common pill be the missing piece for stubborn eye disease?
Disease control Recruiting nowThis study is testing if adding a low-dose oral antibiotic (doxycycline) helps patients with wet age-related macular degeneration (AMD) who still have fluid in their eye despite regular anti-VEGF injections. Fifty participants who are 'incomplete responders' to standard treatment…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: University of Iowa • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Gene test could match eye patients to best drug, save vision
Disease control Recruiting nowThis study aims to see if a person's genes can predict which of two common eye injections works better for treating wet age-related macular degeneration (AMD), a leading cause of vision loss. It will follow 630 patients for 3 years, comparing the standard drug ranibizumab with th…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Parc de Salut Mar • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
One-Shot gene therapy could end decades of eye injections for millions
Disease control Recruiting nowThis study is testing a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (wet AMD), a leading cause of vision loss. The goal is to see if this single treatment can help control the disease long-term, potentially freeing patients from the b…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC